In this 90-minute program, panelists will discuss a range of topics related to the interstate commerce ban, including licensee residency requirements adopted in many states (and associated litigation); the Dormant Commerce Clause; economic and social equity implications of closed markets; and the possibility of interstate compacts as a stopgap pending federal legalization. Speakers will also address the ban’s impact on medical patients and how pending legislation and post-legalization regulatory schemes may impact licensed operators and other industry participants.
This panel will discuss, among other things: (i) the goals of implementing solid corporate governance infrastructure including transparency, equity among shareholders, and maintaining the integrity and legitimacy of a cannabis company in particular; (ii) the importance of advising clients about best practices for effectively maintaining and enforcing corporate governance systems by, including, but not limited to, adhering to the often-overlooked federal guidelines from the United States Sentencing Commission; and (iii) the importance of implementing corporate governance controls and policies during a company’s infancy; and (iv) lessons learned from high-profile cannabis companies whose poor corporate governance practices had a damaging impact, including companies like Namaste Technologies.
This panel will discuss the most relevant issues within this area and the best practices applied by leading practitioners in this field. The panel will provide an overview of financing opportunities and methods, timing for investments and other financing vehicles, and positioning your clients for responsible growth.
Take a look at how to shore up those international supply chain needs, the potential of interstate commerce under state-implemented Memoranda of Understanding, and the future of supply chain consistency in a post-legalized world.
Niall will discuss cannabis jurisdiction, legislation, regulation, Medical Cannabis Access Programme (MCAP, the Specified Controlled Drugs (Cannabis-Based Medical Products), indications, CBD - Novel Foods (Conflict of Laws), and adult use in the Republic of Ireland.
